Clinical trial
A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia
NCT01725204 is registered in ClinicalTrials.gov with Norwegian University of Science and Technology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia
- Lead sponsor
- Norwegian University of Science and Technology
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2012
- Completion date
- May 31, 2016
- Enrollment
- 40 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.